The efficacy of anti-PD-1-based therapies for multiple cancers, such as melanoma, bladder, lung cancers, and Hodgkin lymphoma, has been overwhelmingly demonstrated by clinical trials and experimental murine models. The gene discussed is PDCD1; the disease is melanoma.